Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Microprolactinoma: medical or surgical treatment as first line approach? The case for medical therapy.

Literature DB >> 10800767

Microprolactinoma: medical or surgical treatment as first line approach? The case for medical therapy.

D A Rees¹, J S Davies, M F Scanlon.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2000 PMID： 10800767 DOI： 10.1007/BF03343691

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

× No keyword cloud information.

13 in total

1. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.

Authors: M F Scanlon; J R Peters; J Salvador; S H Richards; R John; S Howell; E D Williams; J P Thomas; R Hall
Journal: Clin Endocrinol (Oxf) Date: 1986-04 Impact factor: 3.478

2. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.

Authors: L Duranteau; P Chanson; A Lavoinne; S Horlait; J Lubetzki; J M Kuhn
Journal: Clin Endocrinol (Oxf) Date: 1991-01 Impact factor: 3.478

3. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

Authors: A Colao; A Di Sarno; F Sarnacchiaro; D Ferone; G Di Renzo; B Merola; L Annunziato; G Lombardi
Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958

4. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.

Authors: H A Sawers; O J Robb; D Walmsley; F M Strachan; J Shaw; J S Bevan
Journal: Clin Endocrinol (Oxf) Date: 1997-03 Impact factor: 3.478

5. Dopamine agonists and pituitary tumor shrinkage.

Authors: J S Bevan; J Webster; C W Burke; M F Scanlon
Journal: Endocr Rev Date: 1992-05 Impact factor: 19.871

6. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.

Authors: C Wang; K S Lam; J T Ma; T Chan; M Y Liu; R T Yeung
Journal: Clin Endocrinol (Oxf) Date: 1987-09 Impact factor: 3.478

7. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors: J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal: N Engl J Med Date: 1994-10-06 Impact factor: 91.245

Microprolactinoma: medical or surgical treatment as first line approach? The case for medical therapy.

1. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.

2. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.

3. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.

4. An audit of the diagnostic usefulness of PRL and TSH responses to domperidone and high resolution magnetic resonance imaging of the pituitary in the evaluation of hyperprolactinaemia.

5. Dopamine agonists and pituitary tumor shrinkage.

6. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal.

7. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

8. Osteoporosis in men with hyperprolactinemic hypogonadism.

9. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea.

10. A survey of the current methods used in the UK to assess pituitary function.

1. Effect of dopaminergic drug treatment on surgical findings in prolactinomas.